61results about How to "Meet the needs of clinical treatment" patented technology

The invention provides a pharmaceutical composition for treating embolism and a preparation method thereof, the pharmaceutical composition comprises a hydroxyl-contained biocompatible polymer materialand a monomer containing unsaturated double bonds and anion groups, as well as a polymer generated by polymerization reaction of an optional vinyl monomer, wherein the polymerization is initiated through free radicles, and bleomycin or pingyangmycin is combined on the anion groups of the generated polymer. The preparation method combines the bleomycin or the pingyangmycin on a carrier of the polymer, thereby being capable of fully playing the dual effects of an anti-tumor antibiotic and a hardening agent owned by the bleomycin or the pingyangmycin during the embolism treatment. The anion partof the polymer can be properly combined with the bleomycin or the pingyangmycin which is rich in amino groups, thereby not only realizing the higher drug loading, but also leading the drug in an emboliaztion agent to be exchanged by cation in human body, and further realizing the slow release. In addition, the embolic carrier of the polymer has the advantages of simple prepration technology andlow cost, thereby being applicable to large-scale industrial production.

The invention discloses a transdermal patch containing pramipexole. The transdermal patch comprises a medicine carrying pressure-sensitive adhesive layer, the pramipexole, solvent and penetration enhancer, wherein the medicine carrying pressure-sensitive adhesive layer comprises acrylate pressure-sensitive adhesive containing carboxyl base groups and acrylate pressure-sensitive adhesive containing hydroxyl base groups, which form mixed pressure-sensitive adhesive; the pramipexole is dissolved in the acrylate mixed pressure-sensitive adhesive, with the content being 10 to 30 weight percent; the content of the mixed pressure-sensitive adhesive is 50 to 80 weight percent; the content of the solvent is 5 to 20 weight percent; the content of the penetration enhancer is 2 to 15 weight percent. The pramipexole can be dissolved in a mixed pressure-sensitive adhesive patch in a high concentration way and is not crystallized, the medicine availability is high, the pramipexole has good stability in pressure-sensitive adhesive matrix, and can be continuously administrated for 5 to 7 days in a transdermal way at a relatively stable permeation rate of being larger than 5.0 micrograms/cm2/h, and the application area of a pramipexole patch is smaller than 40cm2.

The invention discloses a nanometer vauqueline liposome and preparation method which consists of dissolving strychnine, lecithin and cholestrin into organic solvent with a predetermined volume, removing organic solvent from the solution through depressed evaporation for film forming, charging microcosmic salt cushioning solution containing a predetermined concentration of surface active agent, and carrying out swelling, free assembling, ultrasonic dispersing. The prepared strychnine liposome suspending liquid can be used for treating various diseases including gout, arthritis and traumatic injury.

The invention provides a medicine composite used for embolotherapy and acesodyne and a preparation method thereof. The medicine composite comprises a biocompatibility macromolecular compound containing hydroxy, a monomer containing unsaturated double bond and anion group, a polymer, and local anesthetic containing amino group, wherein the polymer is generated through a polymerization reaction of an optional vinyl monomer and the polymerization reaction is initiated by free radicals, and the local anesthetic is combined to an anion group of the generated polymer. In the invention, lidocaine hydrochloride is combined to a polymer carrier; which can give full play to the acesodyne effect of the local anesthetic in the embolotherapy; the anion part of the polymer can properly combine with the local anesthetic containing the amino group, which can both realize higher medicine loading capacity and enable the medicine in an emboliaztion agent to be exchanged by cations in vivo and then slowly released. Moreover, the polymer emboliaztion carrier has simple technology, low cost, and suitability for large scale industrial production.

An antivirus medicine in the form of capsule is prepared from zedoary, oil as primary component, semisynthetic glycerine ester of fatty acid, polyethanediol and surfactant through proportioning, heating zedonary oil to 30-150 deg.c, sieving by 40-100 meshes, mixing with polyethanediol and surfactant, sirring for 30-60 min, and loading in capsule at 10-60 deg.C. Its advantages are high curative effect and no toxic by-effect.

The present invention belongs to the technical field of cells and specifically relates to a high-efficiency induction culture method for preparing natural killer NK cells. The high-efficiency induction culture method for preparing natural killer NK cells mainly includes the following steps: S1, during a preparation stage, using a cell culture bottle coated with recombinant human fibronectin and CD16 antibody; S2, conducting peripheral blood mononuclear cell induction culture; S3, conducting expansion culture; and S4, using a trypan blue staining method and counting cells with a cell counting plate to calculate cell number and cell viability. The provided method can enable the NK cells to proliferate in large quantities, obtains the natural killer NK cells with high quantity, high viabilityand high quality, at the same time, has high safety and can meet needs of clinical treatment.

The invention discloses a correction device membrane and a correction device. The correction device membrane comprises a first soft polymer layer, a hard polymer layer and a second soft polymer layerwhich are combined from top to bottom in sequence; the thicknesses of the first soft polymer layer and the second soft polymer layer are smaller than the thickness of the hard polymer layer; for the hard polymer layer, the yield elongation is larger than 4%, the breaking elongation is larger than 70%, the tensile modulus is larger than 150,000 psi, and the flexural modulus is larger than 150,000 psi; for the first soft polymer layer and the second soft polymer layer, the hardness is 60 A-85 D, the ultimate tensile strength is larger than 5,000 psi, the breaking elongation is 180-220%, and theflexural modulus is larger than 35,000 psi. Through structural design of the correction device membrane, the orthodontics membrane generates more continuous, stable and effective correction force, teeth of a patient can be moved to the expected positions, the balance, stability and attractiveness of the mouth-jaw system are achieved, and the satisfied orthodontics effect is achieved.

The invention relates to a human bone marrow cell processing kit and a cell processing method. The human bone marrow cell processing kit is characterized by consisting of the following three reagents: No.1 reagent which, as a thinner, is 0.5-20% of a sodium chloride injection or PBS (poly butylenes succinate) liquid, No.2 reagent which, as a precipitator, is 0.5-20% of hydroxyethyl starch or methylcellulose, and No.3 reagent which, as layering liquid, is prepared from ficoll and meglumine diatrizoate and is 1.0-1.2 in density. The cell processing method comprises the following steps: adding marrow containing sodium citrate anti-coagulation liquid to a high-capacity nutrient solution bottle which contains the No.1 reagent, and then adding the No.2 reagent and uniformly shaking; standing by, sucking upper cell liquid after layering and centrifuging for 1-20min, thinning the cell liquid by virtue of normal saline after the cell liquid is centrifuged and concentrated and paving the normal saline on the upper layer of No.3 liquid, then centrifuging so that a stem cell layer is separated, collecting the stem cell layer, and cleaning cells by virtue of normal saline for later use. The cell processing method is strong in operability, high in clinical safety and convenient for clinical popularization; and the kit is easy for storage and transportation, applicable to industrial production, and convenient and rapid to use.

The invention discloses a concentration gradient rhIL-2 dependent iNKT cell amplification method and an application thereof. The method comprises the following steps: (1) extracting peripheral blood mononuclear cells PBMC; (2) adding [alpha]-GalCer, which is 100ng/ml in final concentration, to the PBMC cells which are extracted in the step (1), and conducting cultivation for 48h; and (3) gradually increasing an rhIL-2 concentration in a culture medium in the cells which are cultivated in the step (2) in a gradient mode. According to the cell amplification method provided by the invention, when the iNKT cells are collected on the 21st day of cultivation, the quantity of the iNKT cells is increased by 100,000 times, including more than 90% of CD4-iNKT cells which have effects of up-regulating immune reaction and directly killing tumors. The iNKT cells, which are activated and amplified by virtue of the method provided by the invention, are higher in amplification efficiency, and the method can selectively amplify the Th1-like iNKT cells and enhance functions of in vitro amplification iNKT cell immunity as well as tumor immunity surveillance and killing.

The invention discloses a ciprofloxacin dry powder inhaler and a preparation method thereof. The dry powder inhaler is prepared from a drug and a binary auxiliary material, wherein the drug accounts for 80 to 20 percent by mass of the dry powder inhaler, the binary auxiliary material accounts for 20 to 80 percent by mass of the dry powder inhaler, and the binary auxiliary material comprises a mucus diluting agent and biological adhesive protein; the mucus diluting agent is at least one of mannitol, ambroxol hydrochloride, aminothiopropionic acid, and bromhexine hydrochloride; and the biological adhesive protein is at least one of silk fibroin, albumin or spidroin. The dry powder inhaler prepared by the invention is good in mobility, good in aerodynamic performance, capable of targeting thedrug to lung and capable of effectively increasing the local concentration of the drug, has mucus diluting and biological mucosa adsorption characteristics, and is particularly suitable for a patientwith bronchiectasia caused by the chronic infection of the lung.

The invention pertains to the technical field of a new material of medicines, relating to antibiotic /TCP nanocomposite and a method thereof. The antibiotic /TCP nanocomposite provided by the invention is a ball-type porous material which consists of antibiotic and TCP and the matter motes with nanometer size are absorbed on the supporting framework of organic matter. The adjustable range of the ball-type size is from a plurality of hundred nanometers to dozens of microns. The surface of the ball is provided with a portiforium structure. The antibiotic /TCP nanocomposite is a new-type anti-infective bone implanting material which has high drug loading and good re-absorption rate and can control slow releasing rate of drugs.

The invention relates to a surgical robot path planning method, system and device and a storage medium, and the method comprises the steps: obtaining a three-dimensional image model of a to-be-operated object in a target region, and formulating one or more operation paths based on a preset target point and a target point; performing intraoperative registration of the robot; and calculating each operation path to judge whether the robot can plan all the operation paths, if not, adjusting the object to be operated until all the operation paths can be planned, and sending all the plannable operation paths to a controller of the robot. The operation efficiency of a patient can be effectively improved, and the operation risk is reduced.